Cargando…

Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial

PURPOSE: To evaluate a panel of pretreatment clinical and laboratory parameters in metastatic melanoma (MM) in order to verify their impact on response and survival in a single prospective multi-institutional phase III study comparing out-patient chemotherapy (CT) vs bioCT. METHODS: A total of 176 p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guida, Michele, Ravaioli, Alessandra, Sileni, Vanna Chiarion, Romanini, Antonella, Labianca, Roberto, Freschi, Antonio, Brugnara, Salvatore, Casamassima, Addolorata, Lorusso, Vito, Nanni, Oriana, Ridolfi, Ruggero
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2003
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC320500/ https://www.ncbi.nlm.nih.gov/pubmed/14690541 http://dx.doi.org/10.1186/1479-5876-1-13

Ejemplares similares

Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]
por: Chiarion-Sileni, Vanna, et al.
Publicado: (2006)

Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens
por: Chiarion-Sileni, V, et al.
Publicado: (2011)

The cost of unresectable stage III or stage IV melanoma in Italy
por: Maio, Michele, et al.
Publicado: (2012)

No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study
por: Guida, Michele, et al.
Publicado: (2021)

Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma
por: Russo, Irene, et al.
Publicado: (2018)

Consolidation electrochemotherapy with bleomycin in metastatic melanoma during treatment with dabrafenib
por: Valpione, Sara, et al.
Publicado: (2015)

Predictors of toxicity for metastatic melanoma patients treated with ipilimumab
por: Valpione, Sara, et al.
Publicado: (2015)

Melanoma M (Zero): Diagnosis and Therapy
por: Rastrelli, Marco, et al.
Publicado: (2013)

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases
por: Queirolo, Paola, et al.
Publicado: (2014)

Report from the Melanoma Independent Board First Melanoma MIB Conference, 21–22 October 2013
por: Testori, A, et al.
Publicado: (2014)

Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study
por: Guida, M., et al.
Publicado: (2021)

Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme
por: Altomonte, Maresa, et al.
Publicado: (2013)

The Molecular Landscape of Primary Acral Melanoma: A Multicenter Study of the Italian Melanoma Intergroup (IMI)
por: Elefanti, Lisa, et al.
Publicado: (2021)

Surgery and radiotherapy in the treatment of cutaneous melanoma
por: Testori, A., et al.
Publicado: (2009)

A gene expression signature associated with survival in metastatic melanoma
por: Mandruzzato, Susanna, et al.
Publicado: (2006)

Development and External Validation of a Prognostic Nomogram for Metastatic Uveal Melanoma
por: Valpione, Sara, et al.
Publicado: (2015)

The immune cell landscape of metastatic uveal melanoma correlates with overall survival
por: Tosi, Anna, et al.
Publicado: (2021)

Quality assessment of a clinical next-generation sequencing melanoma panel within the Italian Melanoma Intergroup (IMI)
por: Vanni, Irene, et al.
Publicado: (2020)

Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicentre study of the Italian Melanoma Intergroup (IMI)
por: Mandalà, Mario, et al.
Publicado: (2020)

Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma
por: Guida, Michele, et al.
Publicado: (2022)

RIPK3 and AXL Expression Study in Primary Cutaneous Melanoma Unmasks AXL as Predictor of Sentinel Node Metastasis: A Pilot Study
por: Nicolè, Lorenzo, et al.
Publicado: (2021)

Altitude Effect on Cutaneous Melanoma Epidemiology in the Veneto Region (Northern Italy): A Pilot Study
por: Del Fiore, Paolo, et al.
Publicado: (2022)

Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme
por: Chiarion Sileni, Vanna, et al.
Publicado: (2014)

Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy)
por: Aglietta, Massimo, et al.
Publicado: (2021)

Corrigendum to “Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicenter study of the Italian Melanoma Intergroup (IMI)” [Eur J Canc 137 (2020). Pages 30–39]
por: Mandalà, Mario, et al.
Publicado: (2020)

Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients
por: Ridolfi, Ruggero, et al.
Publicado: (2006)

Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised “proof-of-principle” phase II study
por: de Rosa, Francesco, et al.
Publicado: (2014)

The Pattern of Progression to First-Line Treatment with Dabrafenib and Trametinib in Patients with Unresectable or Metastatic, BRAF-Mutated, Cutaneous Melanoma: Results of the Observational T-WIN Study
por: Del Vecchio, Michele, et al.
Publicado: (2023)

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma
por: Long, Georgina V, et al.
Publicado: (2015)

Per- and polyfluoroalkyl substances (PFAS) exposure in melanoma patients: a retrospective study on prognosis and histological features
por: Del Fiore, Paolo, et al.
Publicado: (2022)

IMI Impact of Myopia
por: Sankaridurg, Padmaja, et al.
Publicado: (2021)

IMI Pathologic Myopia
por: Ohno-Matsui, Kyoko, et al.
Publicado: (2021)

IMI 2023 Digest
por: Sankaridurg, Padmaja, et al.
Publicado: (2023)

An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival
por: Mannavola, Francesco, et al.
Publicado: (2020)

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial
por: Ascierto, Paolo A., et al.
Publicado: (2023)

The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale)
por: Guida, Michele, et al.
Publicado: (2018)

Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade
por: Valpione, Sara, et al.
Publicado: (2018)

Melanoma of Unknown Primary: Evaluation of the Characteristics, Treatment Strategies, Prognostic Factors in a Monocentric Retrospective Study
por: Del Fiore, Paolo, et al.
Publicado: (2021)

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort
por: Ascierto, Paolo A, et al.
Publicado: (2014)

Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma
por: Robert, Caroline, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h2jtsc58tj9c1psn2j9j5trk03